Literature DB >> 28078121

Clinical, morphologic, and immunophenotypic characteristics of ampullary carcinomas with an emphasis on SMAD4 expression.

Ahmad Alkhasawneh1, Lizette Vila Duckworth2, Thomas J George3, Neelam V Desai3, Alex J Sommerfeld3, Xiaomin Lu4, Tania Zuluaga Toro2.   

Abstract

BACKGROUND: The purpose of our study was to examine the relationship between clinicopathologic variables and morphologic subtypes in ampullary carcinoma, with an emphasis on the expression of SMAD4 tumor suppressor gene.
METHODS: Sixty-three cases of ampullary carcinomas resected between 2000-2011 were included in this study. Clinical characteristics and outcome data were recorded. Tumors were classified as pancreatobiliary or intestinal type based on morphology, and immunohistochemical (IHC) studies for cytokeratin 7 (CK7), cytokeratin 20 (CK20), cytokeratin 17 (CK17), and SMAD4 were performed.
RESULTS: Forty-nine percent of the ampullary tumors were pancreatobiliary, 29% were intestinal, and 22% were other variants. Tumors with pancreatobiliary morphology showed worse overall survival than those with intestinal morphology or other variants (P=0.03). A trend for higher stage, recurrence and less survival was seen in cases with negative SMAD4 expression. In multivariate analysis, age group (≤60 vs. >60 years) and expression of CK17 were the most prognostic of survival.
CONCLUSIONS: Ampullary tumors with pancreatobiliary morphology have a worse overall survival, while negative SMAD4 expression is associated with a trend of less survival.

Entities:  

Keywords:  SMAD4; ampulla of Vater (AOV); ampullary carcinoma

Year:  2016        PMID: 28078121      PMCID: PMC5177592          DOI: 10.21037/jgo.2016.06.14

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  26 in total

1.  Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up.

Authors:  Hui Zhou; Nico Schaefer; Martin Wolff; Hans-Peter Fischer
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

2.  Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups.

Authors:  Joyce M Leo; Steve E Kalloger; Renata D Peixoto; Nadia S Gale; Douglas L Webber; David A Owen; Daniel Renouf; David F Schaeffer
Journal:  J Clin Pathol       Date:  2015-10-23       Impact factor: 3.411

3.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases.

Authors:  Narasimhan P Agaram; Jinru Shia; Laura H Tang; David S Klimstra
Journal:  Am J Clin Pathol       Date:  2010-05       Impact factor: 2.493

5.  Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas.

Authors:  Gregory M Sheehan; Bhaskar V S Kallakury; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Jeffrey S Ross
Journal:  Hum Pathol       Date:  2005-11       Impact factor: 3.466

6.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

7.  SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Authors:  Amanda Blackford; Oscar K Serrano; Christopher L Wolfgang; Giovanni Parmigiani; Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; James R Eshleman; Michael Goggins; Elizabeth M Jaffee; Christine A Iacobuzio-Donahue; Anirban Maitra; John L Cameron; Kelly Olino; Richard Schulick; Jordan Winter; Joseph M Herman; Daniel Laheru; Alison P Klein; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Ralph H Hruban
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

8.  Reduced expression of SMAD4 in gliomas correlates with progression and survival of patients.

Authors:  Shi-ming He; Zhen-wei Zhao; Yuan Wang; Ji-pei Zhao; Liang Wang; Fang Hou; Guo-dong Gao
Journal:  J Exp Clin Cancer Res       Date:  2011-07-27

9.  Smad4-expression is decreased in breast cancer tissues: a retrospective study.

Authors:  Christina H Stuelten; Miriam B Buck; Juergen Dippon; Anita B Roberts; Peter Fritz; Cornelius Knabbe
Journal:  BMC Cancer       Date:  2006-01-26       Impact factor: 4.430

10.  Frequent somatic mutations of the APC and p53 genes in sporadic ampullary carcinomas.

Authors:  Y Imai; H Oda; N Tsurutani; Y Nakatsuru; T Inoue; T Ishikawa
Journal:  Jpn J Cancer Res       Date:  1997-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.